Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain.
Particulate hepatitis B core Ag (C protein) (HBcAg) and soluble hepatitis B precore Ag (E protein) (HBeAg) of the hepatitis B virus share >70% of their amino acid sequence and most T and B cell-defined epitopes. When injected at low doses into mice, HBcAg particles prime Th1 immunity while HBeAg protein primes Th2 immunity. HBcAg contains 5-20 ng RNA/microg protein while nucleotide binding to HBeAg is not detectable. Deletion of the C-terminal arginine-rich domain of HBcAg generates HBcAg-144 or HBcAg-149 particles (in which >98% of RNA binding is lost) that prime Th2-biased immunity. HBcAg particles, but not truncated HBcAg-144 or -149 particles stimulate IL-12 p70 release by dendritic cells and IFN-gamma release by nonimmune spleen cells. The injection of HBeAg protein or HBcAg-149 particles into mice primes Th1 immunity only when high doses of RNA (i.e., 20-100 microg/mouse) are codelivered with the Ag. Particle-incorporated RNA has thus a 1000-fold higher potency as a Th1-inducing adjuvant than free RNA mixed to a protein Ag. Disrupting the particulate structure of HBcAg releases RNA and abolishes its Th1 immunity inducing potency. Using DNA vaccines delivered intradermally with the gene gun, inoculation of 1 microg HBcAg-encoding pCI/C plasmid DNA primes Th1 immunity while inoculation of 1 microg HBeAg-encoding pCI/E plasmid DNA or HBcAg-149-encoding pCI/C-149 plasmid DNA primes Th2 immunity. Expression data show eukaryotic RNA associated with HBcAg, but not HBeAg, expressed by the DNA vaccine. Hence, codelivery of an efficient, intrinsic adjuvant (i.e., nanogram amounts of prokaryotic or eukaryotic RNA bound to arginine-rich sequences) by HBcAg nucleocapsids facilitates priming of anti-viral Th1 immunity.
Riedl
Petra
P
Institute of Medical Microbiology and Immunology, University of Ulm, Albert Einstein Allee 11, D-89081 Ulm, Germany.
Stober
Detlef
D
Oehninger
Claude
C
Melber
Karl
K
Reimann
Jörg
J
Schirmbeck
Reinhold
R
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001120:Arginine / Q000378:metabolism*; D001665:Binding Sites / Q000235:genetics / Q000276:immunology; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000276:immunology; D004926:Escherichia coli / Q000235:genetics / Q000276:immunology; D005260:Female; D006512:Hepatitis B Core Antigens / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D006513:Hepatitis B e Antigens / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D007110:Immunity, Active / Q000235:genetics; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009414:Nerve Growth Factors; D017434:Protein Structure, Tertiary / Q000235:genetics; D011506:Proteins / Q000276:immunology* / Q000378:metabolism*; D012329:RNA, Bacterial / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D012367:RNA, Viral / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D018417:Th1 Cells / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D014169:Transformation, Bacterial; D014407:Tumor Cells, Cultured; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D004274:DNA, Recombinant; D006512:Hepatitis B Core Antigens; D006513:Hepatitis B e Antigens; C099695:MANF protein, human; D009414:Nerve Growth Factors; D011506:Proteins; D012329:RNA, Bacterial; D012367:RNA, Viral; D019444:Vaccines, DNA; D018664:Interleukin-12; D007371:Interferon-gamma; D001120:Arginine